PolyPid to receive millions for commercialization of infection-fighting drug

A drug to prevent surgical site infections (SSIs) in abdominal and cardiac surgeries in Europe is to be commercialized after two companies entered an exclusive licensing agreement.

Israel-based PolyPid Ltd and UK-based ADVANZ PHARMA Corp. announced the agreement for lead drug candidate D-PLEX100 yesterday (August 3).

Topline results

Under the terms of the agreement, PolyPid will receive an upfront payment immediately upon signing. It will receive additional development-related milestones for a total of up to $23.5 million: An upfront payment of $2.6 million, up to $12.5 million, contingent upon positive topline results of a SHIELD I phase 3 study, and additional development-related milestones of up to $8.4 million is also expected to be exchanged.

Steffen Wagner, CEO at ADVANZ PHARMA, said: “We are very excited by the potential of D-PLEX100 to effectively prevent SSIs and improve patient outcomes. D-PLEX100 is expected to be an important growth driver for ADVANZ PHARMA. The collaboration with PolyPid is in line with our strategy for the commercialization of specialty and hospital pharmaceuticals in Europe.”

When D-PLEX100 is commercialized,

The post PolyPid to receive millions for commercialization of infection-fighting drug appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like